Which peptides have been studied in weight management?
-
AOD-9604hGH Fragment 176-191
Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.
ModerateNot licensed in the UK -
KisspeptinMetastin
Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.
LimitedNot licensed in the UK -
Setmelanotide
Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.
ModerateLicensed UK medicine
Best recorded finding for each peptide in this area
| Peptide | UK status | Finding | Study type | Evidence grade |
|---|---|---|---|---|
| Cagrilintide | Not licensed in the UK | Standalone Phase 2 weight trial | Human trial | Moderate |
| Liraglutide | Licensed UK medicine | SCALE 56-week weight trials | Human trial | Limited |
| Mazdutide | Not licensed in the UK | GLORY-1, phase 3 in China | Human trial | Strong |
| Retatrutide | Not licensed in the UK | Phase 2 obesity trial | Human trial | Moderate |
| Semaglutide | Licensed UK medicine | Weight change at 68 weeks | Human trial | Strong |
| Setmelanotide | Licensed UK medicine | Acquired hypothalamic obesity | Human trial | Moderate |
| Survodutide | Not licensed in the UK | Phase 3 in obesity without diabetes | Human trial | Strong |
| Tirzepatide | Licensed UK medicine | The SURMOUNT-1 obesity trial | Human trial | Strong |
About this research area
"Weight Management" groups peptides that have been studied for effects on appetite, food intake, energy metabolism or body weight, most commonly incretin-mimetic and amylin-pathway compounds investigated in randomised, placebo-controlled human trials. Published research in this area spans mechanisms such as GLP-1 and GIP receptor agonism, amylin-receptor activation and lipolytic signalling, with study designs ranging from receptor-binding assays through to large multi-centre Phase 3 trials. Inclusion here reflects that a peptide's effect on weight-related endpoints has been formally investigated, not that any outcome, positive, negative or mixed, has been established as reliable.
26 sources in the library relate to this area. See them.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.